2025 Q4 -tulosraportti
75 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 55 | - | - | ||
| 22 | - | - | ||
| 300 | - | - | ||
| 150 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 745 | 745 | 0 | 745 |
| Anonyymi | 4 026 208 | 4 026 208 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 745 | 745 | 0 | 745 |
| Anonyymi | 4 026 208 | 4 026 208 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 min sittenEuroinvester 5:27 PM today. New weight loss study shows advantage of using Wegovy over Mounjaro Both of the extremely popular agents can make the pounds drop off, but apparently not the same pounds. Wegovy and Ozempic have in a new and non-peer-reviewed study shown to have an advantage over competitor Mounjaro. Wegovy and Ozempic have in a new and non-peer-reviewed study shown to have an advantage over competitor Mounjaro. Hannah Beier/Reuters/Ritzau Scanpix ofru Oliver Fruergaard Journalist The weight loss drug Wegovy is possibly better for weight loss than competitor Mounjaro on one very central point. This is stated in a new study, which is not yet peer-reviewed. Both of the extremely popular agents can make the pounds drop off, but apparently not the same pounds. Patients who choose Wegovy thus lose less muscle mass than if they had used Mounjaro, state the researchers behind the study, which was published this week. Loss of muscle mass is one of the very big problems one tries to avoid with weight loss, where the goal is generally to lose fat. According to the study, Mounjaro users lost 1.1 percent more fat-free mass after three months and 2 percent after 12 months. Loss of muscle mass can lead to poorer metabolism and physical function as well as the risk of regaining weight, including fat. All else being equal, loss of muscle mass will result in a higher body fat percentage, and thus what many will see as a worse body composition. To avoid losing muscle mass, experts encourage training muscles and eating sufficient protein during weight loss – furthermore, one should avoid losing weight too quickly. Wegovy is manufactured by the Danish pharmaceutical giant Novo Nordisk with the active substance semaglutide. It is also sold as Ozempic. Mounjaro has the active substance tirzepatide and is produced by American Eli Lilly. The new study comes as the two giants compete fiercely for the weight loss market with their weight loss injections. Mounjaro has previously proven to be superior in several respects, and Eli Lilly has recently had a new weight loss pill approved.
·1 t sittenNovo Nordisk's new data for the drug candidate etavopivater are not "merely solid", believes Novo's research director Martin Holst Lange, who instead calls them "exciting". He says this in an interview with Bloomberg News. Novo was able to publish data earlier on Monday from the company's Phase 3 trial with the candidate etavopivater, which is intended to treat sickle cell anemia, a congenital disease that causes low blood count. In the trial, patients treated with the drug showed a significant reduction in the annual incidence of so-called VOCs – which are a painful complication of the disease – by 27 pct. compared to placebo. And according to the research director, this is important, as "any reduction in painful complications from vaso-occlusive crises (VOC, ed.) in sickle cell anemia will be significant for patients". The time to the first VOC was significantly prolonged with etavopivat with a median of 38.4 weeks versus 20.9 weeks for placebo. In addition, Novo's candidate showed an improvement in hemoglobin response in patients compared to placebo. According to the media, gene therapies for sickle cell anemia are not suitable for treating a global population, so it "makes a big difference" to have other treatments available, says Martin Holst Lange. Novo also managed to initiate another study, Hibiscus 2, before the completion of the aforementioned study. Hibiscus 2 will only be completed once Novo has applied for approval of the candidate, but according to the head of research, it will nevertheless contribute to "increasing the knowledge base" around the drug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
75 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 min sittenEuroinvester 5:27 PM today. New weight loss study shows advantage of using Wegovy over Mounjaro Both of the extremely popular agents can make the pounds drop off, but apparently not the same pounds. Wegovy and Ozempic have in a new and non-peer-reviewed study shown to have an advantage over competitor Mounjaro. Wegovy and Ozempic have in a new and non-peer-reviewed study shown to have an advantage over competitor Mounjaro. Hannah Beier/Reuters/Ritzau Scanpix ofru Oliver Fruergaard Journalist The weight loss drug Wegovy is possibly better for weight loss than competitor Mounjaro on one very central point. This is stated in a new study, which is not yet peer-reviewed. Both of the extremely popular agents can make the pounds drop off, but apparently not the same pounds. Patients who choose Wegovy thus lose less muscle mass than if they had used Mounjaro, state the researchers behind the study, which was published this week. Loss of muscle mass is one of the very big problems one tries to avoid with weight loss, where the goal is generally to lose fat. According to the study, Mounjaro users lost 1.1 percent more fat-free mass after three months and 2 percent after 12 months. Loss of muscle mass can lead to poorer metabolism and physical function as well as the risk of regaining weight, including fat. All else being equal, loss of muscle mass will result in a higher body fat percentage, and thus what many will see as a worse body composition. To avoid losing muscle mass, experts encourage training muscles and eating sufficient protein during weight loss – furthermore, one should avoid losing weight too quickly. Wegovy is manufactured by the Danish pharmaceutical giant Novo Nordisk with the active substance semaglutide. It is also sold as Ozempic. Mounjaro has the active substance tirzepatide and is produced by American Eli Lilly. The new study comes as the two giants compete fiercely for the weight loss market with their weight loss injections. Mounjaro has previously proven to be superior in several respects, and Eli Lilly has recently had a new weight loss pill approved.
- ·1 t sittenNovo Nordisk's new data for the drug candidate etavopivater are not "merely solid", believes Novo's research director Martin Holst Lange, who instead calls them "exciting". He says this in an interview with Bloomberg News. Novo was able to publish data earlier on Monday from the company's Phase 3 trial with the candidate etavopivater, which is intended to treat sickle cell anemia, a congenital disease that causes low blood count. In the trial, patients treated with the drug showed a significant reduction in the annual incidence of so-called VOCs – which are a painful complication of the disease – by 27 pct. compared to placebo. And according to the research director, this is important, as "any reduction in painful complications from vaso-occlusive crises (VOC, ed.) in sickle cell anemia will be significant for patients". The time to the first VOC was significantly prolonged with etavopivat with a median of 38.4 weeks versus 20.9 weeks for placebo. In addition, Novo's candidate showed an improvement in hemoglobin response in patients compared to placebo. According to the media, gene therapies for sickle cell anemia are not suitable for treating a global population, so it "makes a big difference" to have other treatments available, says Martin Holst Lange. Novo also managed to initiate another study, Hibiscus 2, before the completion of the aforementioned study. Hibiscus 2 will only be completed once Novo has applied for approval of the candidate, but according to the head of research, it will nevertheless contribute to "increasing the knowledge base" around the drug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 55 | - | - | ||
| 22 | - | - | ||
| 300 | - | - | ||
| 150 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 745 | 745 | 0 | 745 |
| Anonyymi | 4 026 208 | 4 026 208 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 745 | 745 | 0 | 745 |
| Anonyymi | 4 026 208 | 4 026 208 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
75 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 min sittenEuroinvester 5:27 PM today. New weight loss study shows advantage of using Wegovy over Mounjaro Both of the extremely popular agents can make the pounds drop off, but apparently not the same pounds. Wegovy and Ozempic have in a new and non-peer-reviewed study shown to have an advantage over competitor Mounjaro. Wegovy and Ozempic have in a new and non-peer-reviewed study shown to have an advantage over competitor Mounjaro. Hannah Beier/Reuters/Ritzau Scanpix ofru Oliver Fruergaard Journalist The weight loss drug Wegovy is possibly better for weight loss than competitor Mounjaro on one very central point. This is stated in a new study, which is not yet peer-reviewed. Both of the extremely popular agents can make the pounds drop off, but apparently not the same pounds. Patients who choose Wegovy thus lose less muscle mass than if they had used Mounjaro, state the researchers behind the study, which was published this week. Loss of muscle mass is one of the very big problems one tries to avoid with weight loss, where the goal is generally to lose fat. According to the study, Mounjaro users lost 1.1 percent more fat-free mass after three months and 2 percent after 12 months. Loss of muscle mass can lead to poorer metabolism and physical function as well as the risk of regaining weight, including fat. All else being equal, loss of muscle mass will result in a higher body fat percentage, and thus what many will see as a worse body composition. To avoid losing muscle mass, experts encourage training muscles and eating sufficient protein during weight loss – furthermore, one should avoid losing weight too quickly. Wegovy is manufactured by the Danish pharmaceutical giant Novo Nordisk with the active substance semaglutide. It is also sold as Ozempic. Mounjaro has the active substance tirzepatide and is produced by American Eli Lilly. The new study comes as the two giants compete fiercely for the weight loss market with their weight loss injections. Mounjaro has previously proven to be superior in several respects, and Eli Lilly has recently had a new weight loss pill approved.
- ·1 t sittenNovo Nordisk's new data for the drug candidate etavopivater are not "merely solid", believes Novo's research director Martin Holst Lange, who instead calls them "exciting". He says this in an interview with Bloomberg News. Novo was able to publish data earlier on Monday from the company's Phase 3 trial with the candidate etavopivater, which is intended to treat sickle cell anemia, a congenital disease that causes low blood count. In the trial, patients treated with the drug showed a significant reduction in the annual incidence of so-called VOCs – which are a painful complication of the disease – by 27 pct. compared to placebo. And according to the research director, this is important, as "any reduction in painful complications from vaso-occlusive crises (VOC, ed.) in sickle cell anemia will be significant for patients". The time to the first VOC was significantly prolonged with etavopivat with a median of 38.4 weeks versus 20.9 weeks for placebo. In addition, Novo's candidate showed an improvement in hemoglobin response in patients compared to placebo. According to the media, gene therapies for sickle cell anemia are not suitable for treating a global population, so it "makes a big difference" to have other treatments available, says Martin Holst Lange. Novo also managed to initiate another study, Hibiscus 2, before the completion of the aforementioned study. Hibiscus 2 will only be completed once Novo has applied for approval of the candidate, but according to the head of research, it will nevertheless contribute to "increasing the knowledge base" around the drug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 55 | - | - | ||
| 22 | - | - | ||
| 300 | - | - | ||
| 150 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 745 | 745 | 0 | 745 |
| Anonyymi | 4 026 208 | 4 026 208 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 745 | 745 | 0 | 745 |
| Anonyymi | 4 026 208 | 4 026 208 | 0 | 0 |